Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma.
BACKGROUND
Prolongation of median survival can be achieved for intermediate Barcelona Clinic Liver Cancer stage hepatocellular carcinoma (HCC) by transarterial chemoembolisation (TACE). TACE might induce induction of angiogenic factors, especially in patients not responding to TACE, which might result in further tumour progression with development of new satellite lesions.


METHODS
Here, we report a patient with intermediate stage HCC, who initially responded to TACE, but developed new satellite lesions. After careful discussion, TACE was stopped, and a sequential treatment with sorafenib, a vascular endothelial growth factor receptor and RAF tyrosinkinase inhibitor, was started, resulting in a progression-free survival of 10 months.


CONCLUSIONS
The presented case demonstrates the feasibility of sequential TACE and sorafenib treatment. Results of ongoing controlled, clinical trials in this regard are awaited.
Welker
Martin-Walter
MW
Zangos
Stephan
S
Kriener
Susanne
S
Mönch
Christian
C
Zeuzem
Stefan
S
Trojan
Joerg
J
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001557:Benzenesulfonates / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D018572:Disease-Free Survival; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib
Cancer. 2001 Jun 15;91(12):2386-93
11413529
World J Gastroenterol. 2004 Oct 1;10(19):2878-82
15334691
Hepatology. 2003 Feb;37(2):429-42
12540794
J Natl Cancer Inst. 2008 May 21;100(10):698-711
18477802
Expert Rev Anticancer Ther. 2008 Nov;8(11):1743-9
18983234
BMC Cancer. 2008 Nov 26;8:349
19036146
Am J Gastroenterol. 2008 Apr;103(4):914-21
18177453
Eur J Radiol. 2009 Dec;72(3):505-16
18835117
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
Oncology. 2008;75 Suppl 1:1-12
19092266
Semin Liver Dis. 1999;19(3):329-38
10518312
Eur J Gastroenterol Hepatol. 2001 Mar;13(3):291-4
11293452
Lancet. 2003 Dec 6;362(9399):1907-17
14667750
Crit Rev Oncol Hematol. 2008 Jul;67(1):8-15
18434184